Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW1911 in moderate to severe COPD
NCT06175351Phase 2Active, not recruiting
- Sponsor
- Mabwell
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 9MW1911 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Mabwell. Primary endpoints: Pharmacokinetic characteristics at 36 weeks and Safety and tolerability at 36 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
9MW1911
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06175351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175351.